Literature DB >> 7514771

Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies.

N I Cherny1, H T Thaler, H Friedlander-Klar, J Lapin, K M Foley, R Houde, R K Portenoy.   

Abstract

We performed a combined analysis of the results from four controlled single-dose relative-potency studies to assess the impact of inferred pain mechanism on the response to an opioid drug. A total of 168 patients received 474 administrations of either morphine or heroin, and we assessed the analgesic response during a 6-hour period with visual analog scales. We summarized this as a total pain relief (TOTPAR) score. Two experienced pain clinicians reviewed information about pain characteristics and designated each case according to the inferred pain mechanism (neuropathic, nociceptive, or mixed) and the degree of confidence in the inferred mechanism (definite versus probable/possible). They grouped the cases as follows: nociceptive pain only (n = 205), neuropathic pain only (n = 49), and mixed (n = 220). We compared pain relief achieved by patients with different mechanisms, with TOTPAR adjusted for significant covariates (duration of prior opioid administration, doses of opioid administered in the previous 48 hours, pain intensity at the start of the study, BUN:creatinine ratio, and dose of administered opioid). The adjusted mean TOTPAR score of the group with any neuropathic pain was significantly lower than that of the group with nociceptive pain only (26.1 versus 20.4, p = 0.02). The score of the group with definite nociceptive pain alone (adjusted mean TOTPAR = 28.0) was significantly higher than scores of the groups with possible/probable nociceptive pain (TOTPAR = 19.9), mixed mechanisms (TOTPAR = 20.2), definite neuropathic pain alone (TOTPAR = 20.6), and possible/probable neuropathic pain alone (TOTPAR = 22.9).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514771     DOI: 10.1212/wnl.44.5.857

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Alterations in endogenous opioid functional measures in chronic back pain.

Authors:  Ilkka K Martikainen; Marta Peciña; Tiffany M Love; Emily B Nuechterlein; Chelsea M Cummiford; Carmen R Green; Richard E Harris; Christian S Stohler; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

2.  Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners.

Authors:  Ariel Berger; Piotr Kramarz; Gry Stine Kopperud; John Edelsberg; Gerry Oster
Journal:  Eur J Health Econ       Date:  2007-01-13

Review 3.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study.

Authors:  Daniel Arbaiza; Oscar Vidal
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 5.  Responsible prescribing of opioids for the management of chronic pain.

Authors:  Bruce Nicholson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Oral morphine for cancer pain.

Authors:  Philip J Wiffen; Bee Wee; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-22

7.  Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats.

Authors:  M E Fundytus; K Yashpal; J G Chabot; M G Osborne; C D Lefebvre; A Dray; J L Henry; T J Coderre
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

8.  The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward.

Authors:  Giuseppe Cataldo; Samuel J Erb; Mary M Lunzer; Nhungoc Luong; Eyup Akgün; Philip S Portoghese; Julie K Olson; Donald A Simone
Journal:  Neuropharmacology       Date:  2019-04-07       Impact factor: 5.250

9.  Complex Regional Pain Syndrome.

Authors:  Ok Yung Chung; Stephen P. Bruehl
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

10.  Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment.

Authors:  Adam R Burkey; Peter A Kanetsky
Journal:  J Pain Symptom Manage       Date:  2008-12-06       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.